Shares of InspireMD Inc. fell on Friday after the medical device company reported second-quarter 2026 revenue that missed analyst forecasts, underscoring ongoing challenges in its core markets.
The company, which develops and markets cardiovascular medical devices, disclosed revenue of $12.4 million for the quarter ended June 30, 2026. This figure trailed the $13.8 million average estimate from three analysts surveyed by Refinitiv, according to Investing.com data. The revenue decline of 8% year-over-year reflected softer demand in its primary product lines, the company said.
InspireMD attributed the shortfall to delayed hospital procurement decisions and competitive pricing pressures in the cardiovascular device sector. Chief Executive Officer Marc Cohen noted that while the company maintained its full-year 2026 guidance, the revenue miss highlighted near-term execution risks.
"The Q2 results were impacted by macroeconomic headwinds and inventory adjustments at key distributors," Cohen said in a statement. "We remain focused on expanding our market share through innovation and strategic partnerships."
The stock, which had gained 1.2% in premarket trading, reversed course following the announcement, closing down 6.8% at $4.12. Year-to-date, InspireMD shares are down 15%, underperforming the S&P 500 Healthcare Equipment index, which has gained 8% over the same period.
Analysts at Jefferies maintained a Hold rating on the stock with a $5 price target, citing concerns over near-term revenue visibility despite long-term growth potential in its pipeline. Piper Sandler reiterated an Equal Weight rating, emphasizing the need for evidence of stabilization in hospital spending trends.
InspireMD’s full-year 2026 revenue guidance remains unchanged at $52 million to $55 million, implying a 5% to 10% increase from 2025. The company expects adjusted earnings per share of $0.15 to $0.20 for the year, aligning with prior projections.
Investors will monitor upcoming investor presentations for updates on product launches and market penetration strategies, particularly for its flagship CGuard embolic protection device, which accounts for the majority of its revenue.
